Development
Biogen Inc.
BIIB
$138.60
$3.662.71%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -54.63% | -106.00% | -44.08% | 27.68% | 49.48% |
| Total Depreciation and Amortization | 16.94% | 3.56% | -12.91% | -21.52% | -11.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 90.30% | 137.37% | 93.18% | -71.90% | -45.10% |
| Change in Net Operating Assets | 34.37% | 11,744.44% | -114.87% | 76.41% | -1,395.93% |
| Cash from Operations | 107.14% | -10.38% | -33.88% | 181.40% | -120.88% |
| Capital Expenditure | 24.54% | -25.55% | -92.41% | -15.03% | -67.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 106.22% | 306.34% | -193.44% | -50.21% | 10.47% |
| Cash from Investing | -362.30% | -204.19% | -208.65% | -47.07% | -25.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 84.05% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 152.70% | 3,666.67% | -134.39% | -163.03% | -175.51% |
| Cash from Financing | -8,631.08% | 167.78% | 97.92% | -163.03% | -175.51% |
| Foreign Exchange rate Adjustments | -28.72% | 45.12% | 93.30% | 312.77% | 525.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -383.03% | -132.06% | -131.25% | -1.76% | -135.62% |